✦ LIBER ✦

A Phase I/II Clinical Trial to Evaluate a Combination of Recombinant Human Platelet-Derived Growth Factor-BB and Recombinant Human Insulin-Like Growth Factor-I in Patients with Periodontal Disease

✍ Scribed by Howell, T. Howard; Fiorellini, Joseph P.; Paquette, David W.; Offenbacher, Steven; Giannobile, William V.; Lynch, Samuel E.

Book ID: 121193249
Publisher: American Academy of Periodontology
Year: 1997
Tongue: English
Weight: 625 KB
Volume: 68
Category: Article
ISSN: 0022-3492
DOI: 10.1902/jop.1997.68.12.1186

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase-I trial of the epidermal growth

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors

✍ Matthew G. Fury; Allan Lipton; Katherine M. Smith; Corinne B. Winston; David G. 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 377 KB

116 A phase I clinical trial to evaluate

116 A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer

✍ K. Vallis; R. Reilley; D. Scollard; J. Petronis; C. Caldwell; A. Hendler; G. Loc 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Recombinant human anti–transforming grow

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

✍ Christopher P. Denton; Peter A. Merkel; Daniel E. Furst; Dinesh Khanna; Paul Eme 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

## Abstract ## Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). ## Methods Patients with SSc duration of <18 months were randomly assigned to the place

Efficacy and Safely of a Topical Gel For

Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers: A phase III randomized placebo-controlled double-blind study

✍ Wieman, T. J.; Smiell, J. M.; Su, Y. 📂 Article 📅 1998 🏛 American Diabetes Association 🌐 English ⚖ 806 KB

14 A phase I/II study of recombinant hum

14 A phase I/II study of recombinant human keratinocyte growth factor (KGF) in patients with high risk hematologic malignancies undergoing mismatched related or unrelated donor transplant

✍ C.M. Reynolds; J. Ferrara; H. Raymond; T. Braun; V. Ratanatharathorn; L. Ayash; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Phase I Study of Neratinib in Combinatio

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors

✍ Gandhi, L.; Bahleda, R.; Tolaney, S. M.; Kwak, E. L.; Cleary, J. M.; Pandya, S. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 521 KB